FK 23
Latest Information Update: 28 Mar 2019
Price :
$50 *
At a glance
- Originator Unknown
- Developer Nichi-Nichi Pharmaceutical Co.; Nonindustrial source
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Constipation; Immunosuppression; Neutropenia
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Constipation(In volunteers) in Japan
- 21 Feb 2019 Nichi-Nichi Pharmaceutical and Soiken completesclinical trials in Constipation (In volunteers) in Japan (unspecified route) (UMIN000021097)
- 20 Feb 2016 Clinical trials in Constipation (In volunteers) in Japan (unspecified route)